Resistance potential of the HLA-A2-restricted immunodominant SARS-CoV-2-specific CD8 T cell receptor repertoire to antigenic drift.

Resistance potential of the HLA-A2-restricted immunodominant SARS-CoV-2-specific CD8 T cell receptor repertoire to antigenic drift.

Publication date: Dec 18, 2025

A major concern of COVID-19 is immune escape. While T cells are implicated in protection against severe disease, direct evaluation of their capacity to specifically target SARS-CoV-2 variants remains limited. We aim to narrow this gap by profiling the ability of CD8 T cells to recognize SARS-CoV-2 mutations after vaccination and observe a high degree of phenotype and repertoire diversity. To better understand the breadth of antigen repertoire coverage, we interrogate the ability of SARS-CoV-2 specific TCRs to bind all point mutations of the immunodominant HLA-A2:S epitope. While mutation space coverage is surprisingly vast, specific substitutions are not recognized by the vaccine-elicited repertoire. Structural analyses reveal a TCR sequence-based antigen recognition limitation intrinsic to vaccination. Further investigation reveals that this repertoire ‘hole’ is not present in the naive repertoire, suggesting future immune escape through these potential escape mutations could be relieved by modifications to vaccines.

Open Access PDF

Concepts Keywords
A2 A2
Covid Ability
Severe Antigen
Space Cd8
Vaccine Cov
Escape
Hla
Immune
Immunodominant
Mutations
Potential
Repertoire
Sars
Specific
Vaccination

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Tropicamide
pathway REACTOME Reproduction
disease MESH included
disease MESH CAS
disease MESH infection
pathway REACTOME Immune System
disease MESH APL
disease MESH strains
disease MESH CDR3
disease MESH infectious disease
pathway REACTOME Infectious disease
drug DRUGBANK L-Glutamine
disease MESH recurrence
disease MESH chronic infections
drug DRUGBANK L-Arginine
disease MESH breakthrough infections
disease MESH chronic conditions
disease MESH FBS
drug DRUGBANK Streptomycin
disease MESH APC
drug DRUGBANK Biotin
disease MESH LRS
drug DRUGBANK Flunarizine
drug DRUGBANK Calusterone
disease MESH cls
drug DRUGBANK Dasatinib
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Water
drug DRUGBANK Coenzyme M
drug DRUGBANK Methylergometrine
drug DRUGBANK Proline
disease MESH cancer
disease MESH colorectal cancer
pathway KEGG Colorectal cancer
drug DRUGBANK Guanosine
disease MESH HIV infection
pathway REACTOME HIV Infection
disease MESH hepatitis
disease MESH virus infection
disease MESH re infection
pathway KEGG Viral replication
disease MESH CAR
disease MESH Adenocarcinoma
disease MESH David
drug DRUGBANK Etoperidone

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *